Senesco signs LoI to merge with Fabrus

Senesco Technologies (SNTI +5.1%) agrees to terms and executes a non-binding LoI to merge with privately-held biotech firm Fabrus on an approximately 50-50 basis. A definitive agreement is expected in "early 2014."

Fabrus aims to expand the impact of antibodies aimed at drug targets that are resistant to traditional antibody discovery methods. It has 2 collaborations with "large pharma and biotech companies" and an internal pipeline of antibodies targeting renal cell carcinoma and inflammation.

CEO Leslie Browne: "Fabrus antibodies could complement our eIF5A gene regulatory platform, which has been shown to kill cancer cells, by directing nanoparticle-based therapeutics to the cells of interest."

Making things more interesting: Phillip Frost's Frost Gamma Investments Trust, which recently made an investment in Senesco Technologies as detailed by SA Pro's John H. Ford, made an investment in Fabrus back in 2010.

From other sites
Comments (3)
  • Matija Snuderl
    , contributor
    Comments (335) | Send Message
    Philip Frost's involvement in Senesco is a plus to me. Both companies can have interesting synnergies and create a bigger company for the purpose of uplisting.
    30 Dec 2013, 10:29 AM Reply Like
  • russleehowe
    , contributor
    Comments (80) | Send Message
    Bought SNTI couple of months ago at $3. Looking good. Biotech is the new gold rush! Bought more today.
    30 Dec 2013, 11:02 AM Reply Like
  • russleehowe
    , contributor
    Comments (80) | Send Message
    Check out CYNAF. Up nearly 50% in 2 days. Happy New Year!
    30 Dec 2013, 11:05 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs